Phreesia Q3 revenue $55.9M (+45% YoY); FY22 outlook raised to $211M

Phreesia, Inc.

2022-Q3 EPS reported -$1.44 revenue$155,213,000

Revenue $55.9M, up 45% YoY; net loss $36.3M ($0.71/share) vs $6.7M loss prior year.
Adjusted EBITDA -$17.6M vs +$1.2M a year ago, reflecting increased growth investment.
FY2022 revenue outlook raised to $211M from $195-198M; FY2023 growth guided 20-25%.
Cash $400.4M after follow-on offering generating $245.8M net proceeds.
Agreed to acquire Insignia Health for $35M cash; adds Patient Activation Measure (PAM).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.